

Technology Appraisal Committee Meeting (Committee D)

Minutes: Confirmed

Date and Time: Tuesday 15 May 2018, 10:00 – 17:00

Venue: National Institute for Health and Care Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

Present:	1. Professor Gary McVeigh, Chair	Present for all notes
	2. Dr Lindsay Smith	Present for all notes
	3. Dr Nabeel Alsindi	Present for all notes
	4. Dr Aomesh Bhatt	Present for all notes
	5. Dr Matthew Bradley	Present for all notes
	6. Prof. David Bowen	Present for all notes
	7. Mrs Susan Dutton	Present for all notes
	8. Professor Rachel Elliott	Present for all notes
	9. Mrs Gillian Ells	Present for all notes
	10. Professor Paula Ghaneh	Present for all notes
	11. Dr Peter Hall	Present for all notes
	12. Dr Robert Hodgson	Present for all notes
	13. Dr Bernard Khoo	Present for all notes
	14. Dr David Meads	Present for all notes
	15. Libby Mills	Present for all notes
	16. Malcolm Oswald	Present for all notes
	17. Professor Oluwafemi Oyeboode	Present for all notes
	18. Dr Paula Parvulescu	Present for all notes

In attendance:

Ismahan Abdullah	Administrator, National Institute for Health and Care Excellence	Present for all notes
Mariana Bacelar	ERG Representative, BMJ Group Excellence	Present for notes 17 to 25
Lucy Beggs	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 17 to 40
David Chandler	Patient Expert nominated by Psoriasis and Psoriatic Arthritis Alliance	Present for notes 1 to 13
Ross Dent	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 1 to 16

Steve Edwards	ERG Representative, BMJ Group	Present for notes 17 to 25
Christian Griffiths	Technical Adviser, National Institute for Health and Care Excellence	Present for notes 17 to 27
Sabine Grimm	ERG Representative, Kleijnen Systematic Reviews	Present for notes 1 to 13
Kayleigh Kew	ERG Representative, BMJ Group	Present for notes 17 to 25
Helen Knight	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Dr Eleanor Korendowych	Clinical Expert nominated by British Society for Rheumatology	Present for notes 1 to 13
Kate Moore	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Dr Jon Packham	Clinical Expert nominated by British Society for Rheumatology	Present for notes 1 to 13
Xavier Pouwels	ERG Representative, Kleijnen Systematic Reviews	Present for notes 1 to 13
Carla Renton	Patient Expert nominated by Psoriasis Association	Present for notes 1 to 13
David Thomson Nwamaka Umeweni	CDF team, NHS England Technical Adviser, National Institute for Health and Care Excellence	Present for notes 17 to 25 Present for notes 1 to 16 and 28 to 40
Robert Wolff	ERG Representative, Kleijnen Representative	Present for notes 1 to 13

Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of ixekizumab for treating psoriatic arthritis after DMARDs, alectinib for untreated anaplastic lymphoma kinase positive advanced non-small-cell lung cancer and lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine.
2. The chair announced that this will be Susan Dutton's last committee meeting as a member of the Appraisal Committee and thanked her for her time.
3. Apologies were received from Rebecca Harmston and Sumithra Maheswaran.

Any other Business

4. None

Appraisal of ixekizumab for treating psoriatic arthritis after DMARDs

Part 1 – Open session

5. The Chair welcomed the invited experts: David Chandler, Sabine Grimm, Dr Jon Packman, Xavier Pouwels, Carla Renton and Robert Wolff to the meeting and they introduced themselves to the Committee.
6. The Chair welcomed company representatives from Eli Lilly to the meeting.
7. The Chair asked all Committee members to declare any relevant interests
 - 7.1. Dr Nabeel Alsindi, Dr Aomesh Bhatt, Professor David Bowen, Dr Matthew Bradley, Professor Rachel Elliott, Mrs Gillian Ells, Professor Paula Ghaneh, Dr Robert Hodgson, Dr Bernard Khoo, Dr David Meads, Libby Mills, Mr Malcolm Oswald, Professor Oluwafemi Oyebode, Dr Paula Parvulescu and Dr Lindsay Smith all declared that they knew of no direct or indirect interests for any of the technologies to be considered as part of the appraisal of ixekizumab for treating active psoriatic arthritis after DMARDs.
 - 7.2. Dr Peter Hall declared an indirect interest as his department within NHS Lothian has received research funding from Novartis and Pfizer for an unrelated topic.
 - 7.2.1 It was agreed that this declaration would not prevent Dr Peter Hall from participating in this section of the meeting.
 - 7.3. Susan Dutton declared an indirect financial interest as she is involved in a psoriatic arthritis trial. The trial is funded by an NIHR Clinical Scientist Award and includes funding for the Oxford Clinical trials Research Unit (OCTRU), University of Oxford. She is fully funded by OCTRU and will be overseeing the statistician working in the trial management group.
 - 7.3.1. It was agreed that this declaration would not prevent Susan Dutton from participating in this section of the meeting.
8. The Chair asked all NICE Staff to declare any relevant interests.
 - 8.3. All declared that they knew of no direct or indirect interests for any of the technologies to be considered as part of the appraisal of ixekizumab for treating active psoriatic arthritis after DMARDs.
9. The Chair asked all other invited guests to declare their relevant interests.
 - 9.3. David Chandler, Sabine Grimm, Xavier Pouwels, Carla Renton and Robert Wolff all declared that they knew of no direct or indirect interests for any of the technologies to be considered as part of the appraisal of ixekizumab for treating active psoriatic arthritis after DMARDs.
 - 9.4. Dr Jon Packham declared an indirect interest as his wife runs a training and consultancy business supplying the pharmaceutical industry.

9.4.1. It was agreed that this declaration would not prevent Dr Packham from participating in this section of the meeting.

10. The Chair introduced the lead team, Dr Nabeel Alsindi and Malcolm Oswald who gave presentations on the clinical effectiveness and cost effectiveness of ixekizumab for treating psoriatic arthritis after DMARDs.
11. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
12. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
13. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

14. Discussion on confidential information continued. This information was supplied by the company.
15. The Committee continued to discuss the clinical and cost effectiveness of ixekizumab for treating psoriatic arthritis after DMARDs.
 - 15.3. The committee decision was based on consensus.
16. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Appraisal of alectinib for untreated anaplastic lymphoma kinase positive advanced non-small-cell lung cancer

Part 1 – Open session

17. The Chair welcomed the invited experts: Mariana Bacelar, Steve Edwards, Kayleigh Kew and David Thomson to the meeting and they introduced themselves to the Committee.
18. The Chair welcomed company representatives from Roche to the meeting.
19. The Chair asked all Committee members to declare any relevant interests
 - 19.3. Dr Nabeel Alsindi, Dr Aomesh Bhatt, Professor David Bowen, Dr Matthew Bradley, Mrs Susan Dutton, Professor Rachel Elliott, Mrs Gillian Ells, Professor Paula Ghaneh, Dr Robert Hodgson, Dr Bernard Khoo, Dr David Meads, Libby Mills, Mr Malcolm Oswald, Professor Oluwafemi Oyebode, Dr Paula Parvulescu and Dr Lindsay Smith all declared that they knew of no direct or indirect interests for any of the technologies to be considered as part of the appraisal of alectinib for untreated anaplastic lymphoma kinase positive advanced non-small-cell lung cancer.

- 19.4. Dr Peter Hall declared an indirect interest as his department within NHS Lothian has received research funding from Novartis and Pfizer for an unrelated topic.
19.4.1. It was agreed that this declaration would not prevent Dr Peter Hall from participating in this section of the meeting.
20. The Chair asked all NICE Staff to declare any relevant interests.
- 20.3. All declared that they knew of no direct or indirect interests for any of the technologies to be considered as part of the appraisal.
21. The Chair asked all other invited guests to declare their relevant interests.
- 21.3. All declared that they knew of no direct or indirect interests for any of the technologies to be considered as part of the appraisal.
22. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
23. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
24. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
25. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

26. Discussion on confidential information continued. This information was supplied by the company.
- 26.3. The Committee continued to discuss the clinical and cost effectiveness of alectinib for untreated anaplastic lymphoma kinase positive advanced non-small-cell lung cancer.
- 26.4. The committee decision was based on consensus.
27. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Appraisal of lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine

Part 1 – Open session

28. The Chair welcomed the invited expert: David Thomson to the meeting and they introduced themselves to the Committee.
29. The Chair welcomed company representatives from Bayer and Eisai to the meeting.
30. The Chair asked all Committee members to declare any relevant interests
 - 30.3. Dr Nabeel Alsindi, Dr Aomesh Bhatt, Prof. David Bowen, Dr Matthew Bradley, Mrs Susan Dutton, Prof. Rachel Elliott, Mrs Gillian Ells, Prof. Paula Ghaneh, Dr Robert Hodgson, Dr Bernard Khoo, Dr David Meads, Libby Mills, Mr Malcolm Oswald, Prof. Oluwafemi Oyebode, Dr Paula Parvulescu and Dr Lindsay Smith all declared that they knew of no direct or indirect interests for any of the technologies to be considered as part of the appraisal of lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine.
 - 30.4. Dr Peter Hall declared an indirect interest as his department within NHS Lothian has received research funding from Novartis and Pfizer for an unrelated topic.
 - 30.4.1. It was agreed that this declaration would not prevent Dr Peter Hall from participating in this section of the meeting
31. The Chair asked all NICE Staff to declare any relevant interests.
 - 31.3. All declared that they knew of no direct or indirect interests for any of the technologies to be considered as part of the appraisal of lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine.
32. The Chair asked all other invited guests to declare their relevant interests.
 - 32.3. All declared that they knew of no direct or indirect interests for any of the technologies to be considered as part of the appraisal of lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine.
33. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
34. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
35. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
36. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

37. Discussion on confidential information continued. This information was supplied by the company.

38. The Committee continued to discuss the clinical and cost effectiveness of lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine.

38.3. The committee decision was based on consensus.

39. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Date, time and venue of the next meeting

40. Tuesday 12 June 2018, 10:00 – 17:00 at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT.